Bisphosphonate compounds and methods for bone resorption...

Details Bisphosphonate compounds and methods for bone resorption... Bisphosphonate compounds and methods for bone resorption...

2010-06-28

2011-12-06

Aulakh, Charanjit (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C546S022000, C435S183000

Reexamination Certificate

active

08071573

ABSTRACT:
Bisphosphonate compounds and related methods of making and using are disclosed, including pyridinium-1-yl, quinolinium-1-yl, and related compounds. The activity of compounds is disclosed in the context of functional assays such asLeishmania majorfarnesyl diphosphate synthase (FPPS) inhibition,Dictyostelium discoideumgrowth inhibition, human gamma delta T cell activation, and bone resorption. The applicability of bisphosphonate compounds in the context of parasitic infections, for example against trypanosomes, is disclosed. Further potential applications of the invention are disclosed regarding the treatment of one or more conditions such as bone resorption disorders, cancer, bone pain, infectious diseases, and in immunotherapy.

REFERENCES:
patent: 4608368 (1986-08-01), Blum et al.
patent: 4621077 (1986-11-01), Rosini et al.
patent: 4711880 (1987-12-01), Stahl et al.
patent: 4777163 (1988-10-01), Bosies et al.
patent: 4810486 (1989-03-01), Kelly et al.
patent: 4859472 (1989-08-01), Demmer et al.
patent: 4871720 (1989-10-01), Jaeggi
patent: 4927814 (1990-05-01), Gall et al.
patent: 4939130 (1990-07-01), Jaeggi et al.
patent: 5196409 (1993-03-01), Breuer et al.
patent: 5227506 (1993-07-01), Saari et al.
patent: 5294608 (1994-03-01), Lang et al.
patent: 5312954 (1994-05-01), Breuer et al.
patent: 5338731 (1994-08-01), Breuer et al.
patent: 5462932 (1995-10-01), Brenner et al.
patent: 5583122 (1996-12-01), Benedict et al.
patent: 5639653 (1997-06-01), Bloom et al.
patent: 5719303 (1998-02-01), Yoshida et al.
patent: 5756423 (1998-05-01), Cromartie et al.
patent: 5994329 (1999-11-01), Daifotis et al.
patent: 6015801 (2000-01-01), Daifotis et al.
patent: 6057306 (2000-05-01), Wilson et al.
patent: 6096342 (2000-08-01), Dansereau et al.
patent: 6143326 (2000-11-01), Mockel et al.
patent: 6165513 (2000-12-01), Dansereau et al.
patent: 6214812 (2001-04-01), Karpeisky et al.
patent: 6225294 (2001-05-01), Daifotis et al.
patent: 6294196 (2001-09-01), Gabel et al.
patent: 6372728 (2002-04-01), Ungell
patent: 6410520 (2002-06-01), Cazer et al.
patent: 6541454 (2003-04-01), Breuer et al.
patent: 6544967 (2003-04-01), Daifotis et al.
patent: 6548042 (2003-04-01), Arstad et al.
patent: 6562974 (2003-05-01), Cazer et al.
patent: 6638920 (2003-10-01), Thompson
patent: 6696427 (2004-02-01), Jomaa
patent: 6753324 (2004-06-01), Jomaa
patent: 6984400 (2006-01-01), Golomb et al.
patent: 7008645 (2006-03-01), Golomb et al.
patent: 7358361 (2008-04-01), Sanders et al.
patent: 7425549 (2008-09-01), Little et al.
patent: 7560490 (2009-07-01), Zanetti et al.
patent: 7645460 (2010-01-01), Dansereau et al.
patent: 7687482 (2010-03-01), Oldfield et al.
patent: 7745422 (2010-06-01), Sanders et al.
patent: 2002/0042539 (2002-04-01), Arstad et al.
patent: 2004/0087554 (2004-05-01), Blum et al.
patent: 2005/0113331 (2005-05-01), Prniak et al.
patent: 2006/0079487 (2006-04-01), Sanders et al.
patent: 2007/0275931 (2007-11-01), Oldfield et al.
patent: 2008/0255070 (2008-10-01), Oldfield et al.
patent: 2008/0318906 (2008-12-01), Sanders et al.
patent: 2010/0316676 (2010-12-01), Sanders et al.
patent: 3719513 (1988-12-01), None
patent: 19738005 (1999-03-01), None
patent: 19859668 (1999-12-01), None
patent: 55098193 (1980-07-01), None
patent: 172268 (1997-08-01), None
patent: 1022970 (1983-06-01), None
patent: WO 94/20508 (1994-09-01), None
patent: WO 95/34207 (1995-12-01), None
patent: WO 97/08178 (1997-03-01), None
patent: WO 97/12619 (1997-04-01), None
patent: WO 00/03677 (2000-01-01), None
patent: WO 02/11704 (2002-02-01), None
patent: WO 02/076515 (2002-10-01), None
patent: WO 03/021031 (2003-03-01), None
patent: WO 03/075741 (2003-09-01), None
patent: WO 03/097655 (2003-11-01), None
patent: WO 2004/024165 (2004-03-01), None
patent: WO 2004/050096 (2004-06-01), None
patent: WO 2004/060327 (2004-07-01), None
patent: WO 2005/023270 (2005-03-01), None
patent: WO 2005/027842 (2005-03-01), None
patent: WO 2006/039721 (2006-04-01), None
patent: WO 2007/109585 (2007-09-01), None
patent: WO 2008/128056 (2008-10-01), None
Dunford, J.E. et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmaco. Exp. Ther., vol. 296, pp. 235-242, 2001.
Martin, M.B. et al.: Bisphosphonates inhibit the growth of trypanosoma brucei, trypanosoma cruzi, leishmania donovani, taxoplasma gondii and plasmodium falciparum. J. Med. Chem., vol. 44, pp. 909-916, 2001.
Alferev, I.S. et al. : Reactions of vinylidenediphosphonic acid with nucleophiles. Russian Chem. Bullet., vol. 44, pp. 1528-1530, 1995.
Alfer'ev et al. (1983) “Reactions of Vinylidenediphosphonic Acid with Nucleophiles. 1. Addition of Alipathic Amines,”Bull. Acad. Sci. USSR Div. Chem. Sci.32:2515-2518 (in English).
Alfer'ev et al. (1984) “Addition of Nucleophilic Agents to Vinylidenediphosphonic Acid. Communication 2. Reactions of Vinylidenediphosphonic Acid with Primary Amines, Ammonia, and Hydrazine,”Bull. Acad. Sci. USSR Div. Chem. Sci.33:1031-1035 (in English).
Alfer'ev et al. (Aug. 1994) “Reactions of Vinylidenediphosphonic Acid with Nucleophiles. 5. Addition of Heterocyclic Amines and Trimethylamine to Vinylidenediphosphonic Acid,”Russian Chem. Bull.44(8):1528-1530.
Alfer'ev et al. (1987) “Reactions of Vinylidenediphosphonic Acid with Nucleophiles. 3. Addition of Thiols,”Russian Chem. Bull.36(4):786-790.
Alfer'ev et al. (1984) “New Bifunctional Reagents for the Study of Cytochrome P450 Active Center Localization in Microsomal Membrane,”Doklady Akademii Nauk SSSR277(2):371-374 Abstract Only.
Amin. et al. (Aug. 1996) “1-Hydroxy-3-(methylpentylamino)-propylidene-1, 1-bisphosphonic Acid as a Potent Inhibitor of Squalene Synthase,”Arzneimittelforschung46:759-762.
Amin et al. (1992) “Bisphosphonates Used for the Treatment of Bone Disorders Inhibit Squalene Synthase and Cholesterol Biosynthesis,”J. Lipid Res.33:1657-1663.
Benaim G. et al. (Web Release Jan. 5, 2006) “Amiodarone has Intrinsic Anti-Trypanosoma cruziActivity and Acts Synergistically with Posaconazole.”J. Med. Chem.49:892-899.
Bergstrom et al. (Jan. 1, 2000) Alendronate is a Specific, Nanomolar Inhibitor of Farnesyl diphosphate synthase, Arch. Biochem. Biophys. 373(1):231-241.
Blattman et al. (Jul. 2004) “Cancer Immunotherapy: A Treatment for the Masses,”Science305:200-205.
Body et al. (2004) “Oral Ibandrinate Improves Bone Pain and Preserves Quality of Life in Patients with Skeletal Metastases Due to Breast Cancer,”Pain111:306-312.
Bouzahzah et al. (Jun. 2005) “Risedronate in the Treatment of Murine Chagas' Disease,”Parasitol. Res.96:184-187.
Brunger et al. (1998) “Crystallography & NMR System A New Software Suite for Macromolecular Structure Determination,”Acta Crystallogr D Biol Crystallogr.54(5):905-921.
Bundgaard, H. (1985) “Design of Prodrugs,”Methods Enzymol.112:309-396.
Bundgaard, H. (1992) “Means to Enhance Penetration. (1) Prodrugs as a Means to Improve the Delivery of Peptide Drugs,”Adv. Drug. Deliv. Rev.8:1-38.
Bundgaard, H.(1991) “Design and Application of Prodrugs,” in;A Textbook of Drug Design and Development,Krosgaard-Larsen et al. Eds., Ch. 5, pp. 113-191.
Burke et al. (Feb. 2004) “Heteromeric Geranyl Diphosphate Synthase from Mint: Construction of a Functional Fusion Protein and Inhibition by Bisphosphonate Substrate Analogs,”Arch. Biochem. Biophys.422 (1):52-60.
Buxton et al. (2004) “Bisphosphonate-ciprofloxin Bound to Skelite is a Prototype for Enhancing Experimental Local Antibiotic Delivery to Injured Bone,”Br. J. Surg.91:1192-1196.
Cao et al. (2006) “[2-(3-Fluoropyridinium-1-yl)-1-hydroxy-1-phosphonoethyl]phosphonate,”Acta Cryst.E62:o1003-01005.
Cao et al. (2006) “[1-Hydroxy-1-phosphono-2-(trimethylphosphonium-1-yl)ethyl]phosphonate Monohydrate,”Acta Cryst.E62:o1055-01057.
Caraglia et al. (2004) “The

Affiliated with

Also associated with

Rating

Bisphosphonate compounds and methods for bone resorption... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bisphosphonate compounds and methods for bone resorption..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bisphosphonate compounds and methods for bone resorption... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4314059